DIEGO LOAIZA: Open Payments
NPI 1033526413 · HACKENSACK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$846 in 48 payments from 15 companies in 2025. Trend: 2023 $1,094 · 2024 $687 · 2025 $846
Food & beverage: $814Education: $32
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $239 |
| AstraZeneca Pharmaceuticals LP | 9 | $143 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $69 |
| Gilead Sciences, Inc. | 4 | $68 |
| Exact Sciences Corporation | 3 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $54 |
| Lilly USA, LLC | 2 | $40 |
| Amgen Inc. | 2 | $32 |
| LeMaitre Vascular, Inc. | 1 | $25 |
| Medtronic, Inc. | 1 | $24 |
Products named: FARXIGA, XIFAXAN, JARDIANCE, Ozempic, Cologuard Collection Kit, BREZTRI, Rybelsus, ARTEGRAFT VASCULAR GRAFT.
Industry payments across NJ — which companies pay providers there.
